scholarly article | Q13442814 |
P50 | author | Karine Faure | Q47503632 |
P2093 | author name string | Teiji Sawa | |
Temitayo Ajayi | |||
David Shimabukuro | |||
Jeanine P. Wiener-Kronish | |||
Leonard R. Allmond | |||
P2860 | cites work | American Journal of Physiology | Q2160146 |
Prognostic Factors of Pneumonia Requiring Admission to the Intensive Care Unit | Q64130019 | ||
Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections | Q70089750 | ||
Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes | Q71664205 | ||
Epidemiological investigation of Pseudomonas aeruginosa nosocomial bacteraemia isolates by PCR-based DNA fingerprinting analysis | Q71779504 | ||
Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa | Q74568549 | ||
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen | Q22122393 | ||
Type III protein secretion systems in bacterial pathogens of animals and plants | Q24548602 | ||
Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway | Q28492720 | ||
Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits | Q28492960 | ||
Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis | Q33489156 | ||
Type III secretion machines: bacterial devices for protein delivery into host cells | Q33639326 | ||
Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. The Greek Pseudomonas Aeruginosa Study Group | Q33661208 | ||
Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa | Q33728775 | ||
In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections | Q33756310 | ||
Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia | Q33853738 | ||
Production of exoenzyme S during Pseudomonas aeruginosa infections of burned mice | Q34086029 | ||
Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. | Q35567132 | ||
Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon | Q35632593 | ||
Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis | Q36532113 | ||
ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system | Q36809802 | ||
Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11. | Q37296163 | ||
Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa | Q40199320 | ||
Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites | Q40206580 | ||
Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections | Q40706274 | ||
Ventilator-associated pneumonia due to Pseudomonas aeruginosa | Q40945554 | ||
Genetic analysis of exoenzyme S expression by Pseudomonas aeruginosa | Q40966513 | ||
ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury | Q41095866 | ||
The exoenzyme S regulon of Pseudomonas aeruginosa | Q41487139 | ||
The contribution of exoproducts to virulence of Pseudomonas aeruginosa | Q43958510 | ||
Antibiotic resistance and virulence properties of Pseudomonas aeruginosa strains from mechanically ventilated patients with pneumonia in intensive care units: comparison with imipenem-resistant extra-respiratory tract isolates from uninfected patien | Q44016762 | ||
Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa | Q44359602 | ||
Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. | Q44912919 | ||
Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury. | Q46005216 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Pseudomonas aeruginosa | Q31856 |
P304 | page(s) | 2158-2160 | |
P577 | publication date | 2003-05-01 | |
P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
P1476 | title | O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa | |
O-Antigen Serotypes and Type III Secretory Toxins in Clinical Isolates of Pseudomonas aeruginosa | |||
P478 | volume | 41 |
Q41671547 | Acquisition and evolution of the exoU locus in Pseudomonas aeruginosa |
Q51732617 | Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. |
Q30416945 | Identification of the mutation responsible for the temperature-sensitive lipopolysaccharide O-antigen defect in the Pseudomonas aeruginosa cystic fibrosis isolate 2192. |
Q30443179 | Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections |
Q30430870 | Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection |
Q34044909 | Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. |
Q33754176 | Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes |
Q43181958 | Pseudomonas aeruginosa: so many virulence factors, so little time |
Q38242626 | Respiratory infections in patients undergoing mechanical ventilation |
Q34999695 | Review: Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa. |
Q41129552 | Serotyping and Cross-Reactivity's Between Different Pseudomonas aeruginosa Isolates Prevalent in Iran |
Q42282641 | Spread of multidrug-resistant Pseudomonas aeruginosa clones in a university hospital. |
Q30441643 | Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice |
Q26852817 | Vaccines for Pseudomonas aeruginosa: a long and winding road |
Search more.